- Home
- IRWD vs TRNO Comparison
IRWD vs TRNO Comparison
Compare IRWD & TRNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRWD
- TRNO
- Stock Information
- Founded
- IRWD 1998
- TRNO 2009
- Country
- IRWD United States
- TRNO United States
- Employees
- IRWD N/A
- TRNO N/A
- Industry
- IRWD Biotechnology: Pharmaceutical Preparations
- TRNO Real Estate
- Sector
- IRWD Health Care
- TRNO Finance
- Exchange
- IRWD Nasdaq
- TRNO Nasdaq
- Market Cap
- IRWD 150.9M
- TRNO N/A
- IPO Year
- IRWD 2010
- TRNO 2010
- Fundamental
- Price
- IRWD $0.70
- TRNO $56.45
- Analyst Decision
- IRWD Buy
- TRNO Hold
- Analyst Count
- IRWD 5
- TRNO 9
- Target Price
- IRWD $4.94
- TRNO $65.89
- AVG Volume (30 Days)
- IRWD 4.2M
- TRNO 937.0K
- Earning Date
- IRWD 05-07-2025
- TRNO 05-20-2025
- Dividend Yield
- IRWD N/A
- TRNO 3.48%
- EPS Growth
- IRWD N/A
- TRNO 6.08
- EPS
- IRWD N/A
- TRNO 1.98
- Revenue
- IRWD $317,676,000.00
- TRNO $408,011,000.00
- Revenue This Year
- IRWD N/A
- TRNO $19.32
- Revenue Next Year
- IRWD N/A
- TRNO $12.60
- P/E Ratio
- IRWD N/A
- TRNO $28.39
- Revenue Growth
- IRWD N/A
- TRNO 18.24
- 52 Week Low
- IRWD $0.59
- TRNO $48.18
- 52 Week High
- IRWD $8.23
- TRNO $71.63
- Technical
- Relative Strength Index (RSI)
- IRWD 29.40
- TRNO 43.59
- Support Level
- IRWD $0.88
- TRNO $55.87
- Resistance Level
- IRWD $0.98
- TRNO $57.89
- Average True Range (ATR)
- IRWD 0.10
- TRNO 1.28
- MACD
- IRWD 0.02
- TRNO 0.32
- Stochastic Oscillator
- IRWD 11.74
- TRNO 46.57
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.